Merck (MRK) Says KEYTRUDA is the First Anti-PD-1 Therapy Approved in China for Advanced Melanoma
Tweet Send to a Friend
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that KEYTRUDA®, Merck’s anti-PD-1 therapy, has ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
